What's in Keun-Sik Hong's pipeline?

Keun-Sik Hong has 1 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Keun-Sik Hong's portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/keun-sik-hong.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Keun-Sik Hong — Portfolio Competitive Intelligence Brief

Keun-Sik Hong pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Experimental: Rosuvastatin/Ezetimibe 10	Experimental: Rosuvastatin/Ezetimibe 10	marketed	Statin/ezetimibe combination	HMG-CoA reductase; NPC1L1 transporter	Cardiovascular

Therapeutic area mix

Cardiovascular · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Keun-Sik Hong:

Cite this brief

Drug Landscape (2026). Keun-Sik Hong — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/keun-sik-hong. Accessed 2026-05-16.